CY1119513T1 - Μεθοδοι και συνθεσεις για την διαγνωση και την θεραπευτικη αγωγη δευτερογενους αυτοανοσης νοσου της πολλαπλης σκληρυνσης - Google Patents
Μεθοδοι και συνθεσεις για την διαγνωση και την θεραπευτικη αγωγη δευτερογενους αυτοανοσης νοσου της πολλαπλης σκληρυνσηςInfo
- Publication number
- CY1119513T1 CY1119513T1 CY20171100709T CY171100709T CY1119513T1 CY 1119513 T1 CY1119513 T1 CY 1119513T1 CY 20171100709 T CY20171100709 T CY 20171100709T CY 171100709 T CY171100709 T CY 171100709T CY 1119513 T1 CY1119513 T1 CY 1119513T1
- Authority
- CY
- Cyprus
- Prior art keywords
- methods
- treatment
- diagnosis
- recommendations
- secondary self
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1075—Isolating an individual clone by screening libraries by coupling phenotype to genotype, not provided for in other groups of this subclass
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/285—Demyelinating diseases; Multipel sclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Abstract
Η εφεύρεση παρέχει μεθόδους διάγνωσης ασθενών με πολλαπλή σκλήρυνση (MS), συμπεριλαμβανομένων μεθόδων ταυτοποίησης ασθενών με πολλαπλή σκλήρυνση, οι οποίοι διατρέχουν αυξημένο κίνδυνο εμφάνισης δευτερογενούς αυτοάνοσης νόσου μετά από μείωση των λεμφοκυττάρων, που προκαλείται, π.χ., από αγωγή με αντίσωμα αντι-CD52. Επίσης, περιλαμβάνονται μέθοδοι επιλογής θεραπευτικών σχημάτων για ασθενείς με MS και αντιδραστήρια χρήσιμα στις παραπάνω μεθόδους.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19565808P | 2008-10-08 | 2008-10-08 | |
US19718708P | 2008-10-24 | 2008-10-24 | |
US19863108P | 2008-11-07 | 2008-11-07 | |
PCT/IB2009/007327 WO2010041149A2 (en) | 2008-10-08 | 2009-10-08 | Methods and compositions for diagnosis and treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1119513T1 true CY1119513T1 (el) | 2018-03-07 |
Family
ID=42061141
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20171100709T CY1119513T1 (el) | 2008-10-08 | 2017-07-04 | Μεθοδοι και συνθεσεις για την διαγνωση και την θεραπευτικη αγωγη δευτερογενους αυτοανοσης νοσου της πολλαπλης σκληρυνσης |
Country Status (22)
Country | Link |
---|---|
US (4) | US20110229470A1 (el) |
EP (2) | EP2344677B1 (el) |
JP (2) | JP5856481B2 (el) |
KR (2) | KR101682730B1 (el) |
CN (1) | CN102245783B (el) |
AU (1) | AU2009302117B2 (el) |
BR (1) | BRPI0920546B1 (el) |
CA (1) | CA2740077A1 (el) |
CY (1) | CY1119513T1 (el) |
DK (1) | DK2344677T3 (el) |
ES (2) | ES2632213T3 (el) |
HK (1) | HK1246364A1 (el) |
HR (1) | HRP20171023T1 (el) |
HU (1) | HUE035208T2 (el) |
IL (1) | IL212069A (el) |
LT (1) | LT2344677T (el) |
MX (1) | MX336835B (el) |
PL (2) | PL3241910T3 (el) |
PT (2) | PT3241910T (el) |
RU (1) | RU2563521C2 (el) |
SI (1) | SI2344677T1 (el) |
WO (1) | WO2010041149A2 (el) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20140469A1 (es) | 2011-05-16 | 2014-04-23 | Genzyme Corp | Induccion de tolerancia inmunologica utilizando metotrexato |
CN110151745A (zh) | 2011-12-13 | 2019-08-23 | Io治疗公司 | 使用rxr激动剂的自身免疫紊乱的治疗 |
PL2855667T3 (pl) * | 2012-05-25 | 2024-03-25 | Cellectis | Sposoby uzyskiwania metodami inżynierii allogenicznych i opornych na immunosupresję limfocytów t do immunoterapii |
CN102786595B (zh) * | 2012-08-03 | 2014-04-23 | 无锡傲锐东源生物科技有限公司 | 抗cd5蛋白单克隆抗体及其用途 |
IL261669B2 (en) | 2016-03-10 | 2023-12-01 | Io Therapeutics Inc | A combination of thyroid hormones and an RXR agonist for the treatment of autoimmune diseases |
CN109963865A (zh) * | 2016-07-19 | 2019-07-02 | 阿雷特发现公司 | 用于检测和治疗肥大细胞活性相关病症的生物标记 |
CN109963570A (zh) | 2017-01-21 | 2019-07-02 | 宁波知明生物科技有限公司 | 芍药苷-6’-o-苯磺酸酯在治疗干燥综合征的应用 |
AU2018335393A1 (en) | 2017-09-20 | 2020-04-02 | Io Therapeutics, Inc. | Treatment of disease with esters of selective RXR agonists |
US11672092B2 (en) * | 2019-11-06 | 2023-06-06 | Steiner Enterprises | Modular electrical distribution system for vehicles |
EP4001919A1 (en) * | 2020-11-13 | 2022-05-25 | Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal | Predictive biomarkers of autoimmunity in patients treated with alemtuzumab |
CN117295948A (zh) * | 2021-05-13 | 2023-12-26 | 建新公司 | 淋巴细胞清除疗法后的继发性自身免疫的新型预测性生物标记物 |
WO2023108012A1 (en) | 2021-12-07 | 2023-06-15 | Io Therapeutics, Inc. | Use of an rxr agonist and taxanes in treating her2+ cancers |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6351720B1 (en) | 1997-10-24 | 2002-02-26 | Mitsubishi Heavy Industries, Ltd. | Trolley camera position detecting apparatus |
US6045501A (en) * | 1998-08-28 | 2000-04-04 | Celgene Corporation | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
US6315720B1 (en) * | 2000-10-23 | 2001-11-13 | Celgene Corporation | Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug |
CN1630664A (zh) | 2001-09-04 | 2005-06-22 | 耶达研究发展有限公司 | 胱冬酶-8结合蛋白及其制备和使用 |
ES2334338T3 (es) | 2001-11-05 | 2010-03-09 | Zymogenetics, Inc. | Antagonistas de il-21. |
US20030124127A1 (en) | 2001-12-06 | 2003-07-03 | Lijun Yang | Targeting leukemia cells |
US20040009150A1 (en) | 2002-06-07 | 2004-01-15 | Nelson Andrew J. | Methods of treating cancer using IL-21 |
AU2004224277A1 (en) | 2003-03-21 | 2004-10-07 | Wyeth | Treating immunological disorder using agonists of interleukin-21/ interleukin-21 receptor |
WO2005030196A2 (en) * | 2003-09-25 | 2005-04-07 | Zymogenetics, Inc. | Methods of treating autoimmune diseases using il-21 |
EP1773394A2 (en) | 2004-08-05 | 2007-04-18 | Wyeth a Corporation of the State of Delaware | Antagonizing interleukin-21 receptor activity |
AU2006340750B2 (en) * | 2005-11-28 | 2013-03-07 | Zymogenetics, Inc. | IL-21 antagonists |
-
2009
- 2009-10-08 CA CA2740077A patent/CA2740077A1/en not_active Withdrawn
- 2009-10-08 US US13/123,188 patent/US20110229470A1/en not_active Abandoned
- 2009-10-08 SI SI200931691T patent/SI2344677T1/sl unknown
- 2009-10-08 MX MX2011003730A patent/MX336835B/es active IP Right Grant
- 2009-10-08 KR KR1020117010362A patent/KR101682730B1/ko active Application Filing
- 2009-10-08 CN CN200980149287.1A patent/CN102245783B/zh active Active
- 2009-10-08 PT PT171592355T patent/PT3241910T/pt unknown
- 2009-10-08 PT PT98043086T patent/PT2344677T/pt unknown
- 2009-10-08 WO PCT/IB2009/007327 patent/WO2010041149A2/en active Application Filing
- 2009-10-08 AU AU2009302117A patent/AU2009302117B2/en active Active
- 2009-10-08 JP JP2011530591A patent/JP5856481B2/ja active Active
- 2009-10-08 HU HUE09804308A patent/HUE035208T2/hu unknown
- 2009-10-08 DK DK09804308.6T patent/DK2344677T3/en active
- 2009-10-08 EP EP09804308.6A patent/EP2344677B1/en active Active
- 2009-10-08 RU RU2011118477/10A patent/RU2563521C2/ru active
- 2009-10-08 ES ES09804308.6T patent/ES2632213T3/es active Active
- 2009-10-08 BR BRPI0920546-2A patent/BRPI0920546B1/pt active IP Right Grant
- 2009-10-08 EP EP17159235.5A patent/EP3241910B1/en active Active
- 2009-10-08 PL PL17159235T patent/PL3241910T3/pl unknown
- 2009-10-08 LT LTEP09804308.6T patent/LT2344677T/lt unknown
- 2009-10-08 PL PL09804308T patent/PL2344677T3/pl unknown
- 2009-10-08 ES ES17159235T patent/ES2784830T3/es active Active
- 2009-10-08 KR KR1020167033277A patent/KR101825457B1/ko active IP Right Grant
-
2011
- 2011-03-31 IL IL212069A patent/IL212069A/en active IP Right Grant
-
2014
- 2014-06-17 JP JP2014124055A patent/JP2014195462A/ja active Pending
-
2016
- 2016-02-02 US US15/013,808 patent/US10598670B2/en active Active
-
2017
- 2017-07-04 HR HRP20171023TT patent/HRP20171023T1/hr unknown
- 2017-07-04 CY CY20171100709T patent/CY1119513T1/el unknown
-
2018
- 2018-05-04 HK HK18105788.5A patent/HK1246364A1/zh unknown
-
2020
- 2020-02-25 US US16/801,009 patent/US11243211B2/en active Active
-
2022
- 2022-01-12 US US17/574,282 patent/US20220349899A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1119513T1 (el) | Μεθοδοι και συνθεσεις για την διαγνωση και την θεραπευτικη αγωγη δευτερογενους αυτοανοσης νοσου της πολλαπλης σκληρυνσης | |
CY1120423T1 (el) | Β7-η1 και pd-1 στη θεραπεια του καρκινωματος νεφρικων κυτταρων | |
Julayanont et al. | Montreal Cognitive Assessment Memory Index Score (MoCA‐MIS) as a Predictor of Conversion from Mild Cognitive Impairment to A lzheimer's Disease | |
CY1120384T1 (el) | Απταμερη θεραπευτικα χρησιμα στην αντιμετωπιση των σχετικων με το συμπληρωμα διαταραχων | |
CY1117817T1 (el) | Υποκατεστημενα ακυλανιλιδια και μεθοδοι χρησης αυτων | |
CY1118660T1 (el) | Συνθεσεις και μεθοδοι για την θεραπεια διαταραχων ματιων | |
CY1113058T1 (el) | Συνδυαστικη θεραπεια για την αντιμετωπιση οφθαλμικων νεοαγγειακων διαταραχων | |
CY1120723T1 (el) | Ανταγωνιστικα αντισωματα il-17 | |
CY1118549T1 (el) | Χρηση anti-vegf αντισωματος σε συνδυασμο με χημειοθεραπεια για τη θεραπευτικη αγωγη του καρκινου του μαστου | |
CY1117286T1 (el) | Μεσα και μεθοδοι για την αντιμετωπιση μυϊκων διαταραχων | |
EA201190043A1 (ru) | Имидазопиразиновые ингибиторы syk | |
CY1117155T1 (el) | Μεσα και μεθοδοι για θεραπευτικη αγωγη dlbcl | |
MA32561B1 (fr) | Anticorps neutralisant le cytomegalovirus humain et leurs utilisations | |
ATE439868T1 (de) | Targetingmittel für molekulare bilderzeugung | |
CY1118663T1 (el) | Μεθοδος αναγνωρισης κινδυνου για διαταραχη του θυρεοειδους | |
ATE553778T1 (de) | Für humanes hepcidin spezifische antikörper | |
ATE530667T1 (de) | Kcnn3 als diagnostisches und therapeutisches target für alzheimer-krankheit | |
CY1119653T1 (el) | Μεθοδος για ταυτοποιηση της ευαισθησιας ενος ασθενους σε θεραπεια αναστολης της τελομερασης | |
Hou et al. | Exploring the employment readiness and return to work status of breast cancer patients and related factors | |
Goldberg et al. | Substantial genetic link between iq and working memory: Implications for molecular genetic studies on schizophrenia. the european twin study of schizophrenia (EUTwinsS) | |
Derman et al. | Recommendations and outcomes from a geriatric assessment guided multidisciplinary clinic prior to autologous stem cell transplant in older patients | |
ATE501276T1 (de) | Verfahren zur gliomdiagnose mit unterscheidung zwischen progressiven und de-novo-formen | |
Argente-Escrig et al. | Clinical, genetic, and disability profile of pediatric distal hereditary motor neuropathy | |
DE602008004556D1 (de) | Zusammensetzungen und verfahren zum nachweis von störungen in verbindung mit histamin | |
MX2021009281A (es) | Metodos de deteccion de legionella. |